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The aim of this study was to investigate the homocysteine
(Hcy) levels and the C677T polymorphism of 5,10-methyl-
enetetrahydrofolate reductase (MTHFR), a crucial factor of
the Hcy metabolism in young women with polycystic ovary
syndrome (PCOS).
Seventy young women with PCOS and another 70 healthy
women with low folate intake were enrolled. Cases and con-
trols were matched for age, body mass index, and allele fre-
quency. Hcy, vitamin B12, and folate levels were measured,
and a genetic analysis of 5,10-MTHFR at nucleotide 677 was
performed in all subjects.
No difference in mean Hcy levels was observed between
PCOS women in comparison to the control group. Considering
the different MTHFR polymorphism, no significant difference
was found in serum Hcy levels between subjects with PCOS
and controls showing CC (10.4  3.1 vs. 9.7  2.9 mol/liter 
SD) and CT genotypes (10.9 3.8 vs. 11.0 3.2 mol/liter SD).
In subjects with a TT homozygous state, a significant (P < 0.05)
difference was observed between PCOS and control women
(11.5  3.9 vs. 22.0  7.8 mol/liter  SD).
In conclusion, our data show that in PCOS women, the se-
rum Hcy levels are normal, and the C677T polymorphism of
MTHFR does not influence the Hcy levels like in controls.
(J Clin Endocrinol Metab 88: 673–679, 2003)
POLYCYSTIC OVARY SYNDROME (PCOS) is one of themost common endocrine diseases of women of fertile
age, affecting up to 10% of women in reproductive age, and
is characterized by hyperandrogenism, chronic anovulatory
cycles, and oligomenorrhea or amenorrhea (1). At present,
PCOS is considered not only a disease that influences fertility
but also a plurimetabolic syndrome (2).
Recent data have shown an increased prevalence of car-
diovascular disease (CVD) in PCOS women (3–6), and sev-
eral studies have evaluated whether there is a higher car-
diovascular morbidity and mortality in these patients (7, 8).
Elevated plasma homocysteine (Hcy) levels are considered
to be an independent risk factor for CVD (9–11). A strong
association between plasma Hcy concentrations and CVD
has been observed (12–16). The mechanism of the Hcy action
on the cardiovascular system, furthermore, is still unknown.
Circulating Hcy levels could be influenced by many de-
terminants (12). Genetic factors play an important role in the
metabolic pathway of Hcy synthesis. Enzymatic defects
caused by genetic mutations induce a significant increase in
Hcy concentrations (17). In the general population, the most
common cause of abnormal serum Hcy levels seems to be a
reduced efficiency of methylenetetrahydrofolate reductase
(MTHFR), an enzyme involved in the folate-dependent rem-
ethylation of Hcy to methionine (18). The C677T mutation, i.e.
alanine to valine substitution at nucleotide 677, in MTHFR
gene causes an impairment of its enzymatic activity (19–26).
When C677T mutation is present in a homozygous state, this
polymorphism results in a variant of MTHFR enzyme, re-
ferred to as the thermolabile MTHFR (18), and in elevated
circulating total Hcy levels (15–16, 27).
At present, no data are available in literature regarding the
relationship between serum Hcy levels and MTHFR poly-
morphism in women with PCOS.
In this view, the aim of this study was to investigate the
serum Hcy levels and the C677T polymorphism of MTHFR
in young women with PCOS.
Patients and Methods
The procedures used were in accordance with the guidelines of the
Helsinki Declaration on human experimentation. The study was ap-
proved by the Institutional Review Board of the University of Naples.
The purpose of the protocol was explained to both the patients and
control women, and written consent was obtained from them before
beginning the study.
Patients
Seventy young women [age, 22.5  4.3 (sd) yr; range, 18–27 yr] with
PCOS were enrolled for the study. PCOS was defined according to
clinical (Ferriman-Gallwey score  8; and/or oligomenorrhea or am-
enorrhea), biological (LH/FSH ratio  2; hyperandrogenism), and ul-
trasonographic findings (28, 29).
Another 70 healthy young volunteer females, matched for age, body
mass index (BMI), and allele frequency, were enrolled and considered
Abbreviations: A, Androstenedione; AUC, area under curve; BMI,
body mass index; CBS, cystathione--synthase; CI, confidence interval;
CV, coefficient(s) of variation; CVD, cardiovascular disease; DHEAS,
dehydroepiandrosterone sulfate; E2, 17-estradiol; Hcy, homocysteine;
MTHFR, methylenetetrahydrofolate reductase; OGTT, oral glucose tol-
erance test; 17-OHP, 17-hydroxyprogesterone; P, progesterone; PCOS,
polycystic ovary syndrome; PRL, prolactin; T, testosterone.
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as the control group. Their healthy state was determined by medical
history, physical and pelvic examination, and complete blood chemistry.
Their normal ovulatory state was confirmed by transvaginal ultrasonog-
raphy and plasma progesterone (P) assay detected during the luteal
phase of the cycle.
To avoid dietary interference, only women with a low folate intake
were enrolled. In the present study, we considered women at low folate
intake when the serum folate levels were below 12.5 nmol/liter (30, 31).
Exclusion criteria for all subjects included pregnancy, hypothyroid-
ism, current use of vitamins, current or previous (within the last 6
months) use of oral contraceptives, glucocorticoids, antiandrogens, ovu-
lation induction agents, antidiabetic and antiobesity drugs, or other
hormonal drugs. None of the patients were affected by any neoplastic,
metabolic, and cardiovascular disorder or other concurrent medical
illness (i.e. diabetes, renal disease, and malabsorptive disorders). All
subjects were nonsmokers and had a normal physical activity, and none
drank alcoholic beverages.
The cases and the controls were genetically unrelated.
Study protocol
At study entry, all subjects underwent venous blood drawing for
complete hormonal assays, lipid profile, glucose, insulin, and Hcy levels,
and MTHFR genetic study.
Glucose and insulin values were detected also after oral glucose
tolerance test (OGTT).
All blood samples were obtained in the morning between 0800 h and
0900 h after a 3-d, 300-g carbohydrate diet, an overnight fasting, and
resting in bed during early follicular phase (d 2–5) of the spontaneous
or P-induced menstrual cycle.
During the same visit, all subjects underwent transvaginal ultra-
sonography, anthropometric measurements, including BMI and waist to
hip ratio, systolic and diastolic blood pressure, echocardiographic as-
sessment, and echocolor-Doppler with evaluation of intima media
thickness.
In the present study, only the data regarding the serum Hcy levels and
the genetic evaluation of MTHFR will be shown and discussed.
Biochemical assay
A butterfly needle was inserted into an antecubital vein, and an iv
saline infusion was given at a rate of approximately 50 ml/h. The
subjects were kept supine throughout the infusion period and were not
allowed to smoke, sleep, or drink alcoholic or caffeinated beverages.
Thirty minutes after the needle insertion, basal blood samples were
obtained to evaluate complete hormonal assays. On these samples the
following hormonal serum levels were measured: LH, FSH, 17-estra-
diol (E2), P, total testosterone (T), androstenedione (A), dehydroepi-
androsterone sulfate (DHEAS), prolactin (PRL), TSH, and SHBG. All
blood samples for each woman were assayed in duplicate determina-
tions and immediately centrifuged, and the serum was stored at 80 C
until analysis. The mean of two hormonal results was calculated.
Plasma PRL, LH, TSH, FSH, E2, P, T, A, and DHEAS were measured
by specific RIA, as previously described (32). Serum 17-hydroxypro-
gesterone (17-OHP) levels were determined using a RIA (DSL 5000,
Diagnostic Systems Laboratories, Inc., Webster, TX) with a sensitivity of
0.5 nmol/liter and intra-assay and interassay coefficients of variation
(CV) of 8.9 and 9.0%, respectively. SHBG levels were measured using an
immunoradiometric assay (Radim S.p.A, Pomezia, Rome, Italy) with a
sensitivity of 2.5 nmol/liter and intra-assay and interassay CV of 5.1%
and 5.2%, respectively.
Glucose and insulin concentrations were measured also 30 min after
insertion of the iv catheter to detect the fasting levels (time 0) before
OGTT. Successively, each subject received 75-g glucose load orally.
Further blood samples (10 ml each) were obtained at 30-min intervals for
the following 3 h during the infusion period (times 30, 60, 90, 120, 150,
and 180 min), and glucose and insulin concentrations were determined.
Plasma glucose levels were determined by the glucose oxidase
method on a Beckman Glucose Analyzer (Beckman Coulter, Inc., Ful-
lerton, CA), with a sensitivity of 0.3 mmol/liter and intra-assay and
interassay CV of 1.0% and 1.2%, respectively. Serum insulin was mea-
sured by a solid-phase chemiluminescent enzyme immunoassay using
commercially available kits (Immunolite, Diagnostic Products, Los An-
geles, CA) with a sensitivity of 2.0U/ml and intra-assay and interassay
CV of 5.5% and 5.8%, respectively.
Glucose tolerance was assessed by World Health Organization cri-
teria (33).
In the PCOS and control groups, the glucose and insulin response to
OGTT was analyzed by calculating the area under curve (AUC). The
AUCs for glucose (AUCglucose) and insulin (AUCinsulin) were determined
according to the mathematical method described by Tai (34) for the
metabolic curves. The AUCglucose/AUCinsulin ratio was also calculated in
each subject (35).
Homocysteine and vitamins assays
Serum Hcy levels were measured by HPLC using a C-18 reverse
phase 25  0.46-cm column and fluorescence detection (Beckman Gold
System, Beckman Coulter, Inc.), and an isocratic buffer consisting of
0.1 m acetate buffer (pH 4.0; containing 20 ml methanol/liter buffer).
Detection was accomplished on a Shimadzu RF535 fluorometric detector
(Shimadzu Corp., Kyoto, Japan; emission , 385 nm; excitation , 515
nm). Ammonium-7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate was
used as a derivative agent of the Hcy thiol residue. Hcy sensitivity of the
assay was greater than 0.25 mol/liter of serum. Quantitation accuracy
was granted by the use of an internal standard (acetyl-cysteine), and the
inter- and intra-assay CV were 2% and 1%, respectively.
Vitamin B12 and folate were analyzed by capillary electrophoresis
(P/ACE 5000 system, Beckman Coulter, Inc., Palo Alto, CA). Separations
were accomplished by the use of a 75-m (internal diameter) silica-fused
capillary with a length to detector of 50 cm. The capillary was filled with
a 10 mm Tris-sodium phosphate buffer (pH 7.56). The applied voltage
was 20 kV, and detection was 200 nm. The inter- and intra-assay CV for
vitamin B12 assay were 7.4% and 6.7%, respectively, and for folate assay,
4.1% and 4.2%, respectively.
DNA analysis
The DNA analysis was performed in the MeriGen Molecular Biology
Laboratory (Naples, Italy). Blood samples were collected in tubes con-
taining disodium-EDTA as anticoagulant and stored at 4 C until DNA
extraction. DNA was extracted by the salt phenol chloroform method
from the buff coat cells (36). The extracted DNA was stored at20 C until
analysis.
Briefly the primers used (5TGAAGGAGAAGGTGTCTGCGGGA 3
exonic and 5AGGACGGTGCGGTGAGAGTG 3 intronic) for the anal-
ysis of the A3 V change generated, by PCR, a 198-bp DNA fragment.
The substitution created a HinfI recognition sequence that digested the
198-bp fragment into 175 and 23-bp fragments. MTHFR genotype was
determined by HinfI digestion of the PCR products, separated by 2%
agarose gel electrophoresis, and visualized under UV light after
ethidium staining, as described by Frosst et al. (18).
Genotypes were expressed as CC for homozygous normal, CT for
heterozygous, and TT for homozygous mutant.
Statistical analysis
Statistical analysis was performed using the SPSS 9.0 (SPSS, Inc.,
Chicago, IL) package. Continuous data were expressed as mean  sd.
A P value less than 0.05 was considered statistically significant.
The characteristics of the patients and the mean plasma hormone
concentrations between the two clinical groups were compared by Stu-
dent’s t test for unpaired data and between and within the different
groups of MTHFR genotypes with the ANOVA.
Student’s t test for unpaired data was also used to evaluate the
differences in mean Hcy, vitamin B12, folate, glucose, and insulin levels
in PCOS and control groups.
A linear regression analysis was performed to study the relationship
between serum Hcy levels and vitamin B12 and folate concentrations.
Allelic and genotypic frequencies were determined from observed
genotype counts, and the expectations of the Hardy-Weinberg equilib-
rium were evaluated by 2 analysis. Differences in the genotype distri-
bution between different groups were assessed by Pearson’s 2 test of
heterogeneity.
ANOVA was used to compare the difference in mean Hcy, vitamin
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B12, folate, AUCglucose, AUCinsulin, and AUCglucose/AUCinsulin ratio after
OGTT between and within the different groups of MTHFR genotypes.
The correlation between AUCglucose, AUCinsulin, and AUCglucose/
AUCinsulin ratio and Hcy levels in PCOS and healthy women, according
to different MTHFR genotype, was studied using a linear regression
analysis.
Results
The demographic and hormonal data of the PCOS and
control groups are reported in Table 1. In the PCOS group,
LH, 17-OHP, T, A, E2, DHEAS, and SHBG were significantly
(P 0.05) different in comparison with healthy women. The
fasting insulin levels were significantly (P  0.05) higher in
PCOS than in control women, whereas no difference in fast-
ing glucose concentrations was observed between groups.
No significant differences were detected in serum vitamin
B12 and folate or in Hcy levels between PCOS and healthy
women.
A significant (P  0.05) inverse correlation was observed
between serum Hcy levels and vitamin B12 (r0.42 and r
0.45 for PCOS and control groups, respectively) and folate
concentrations (r  0.39 and r  0.41 for PCOS and
control groups, respectively).
The mutation rate of C677T in MTHFR is shown in Table 2.
The allelic distribution of MTHFR genotypes was in Hardy-
Weinberg equilibrium for both groups of women. There was a
similar genotype distribution between the PCOS and control
groups (Table 2).
No difference in demographic data was detected between
or within the different groups of MTHFR genotypes (data not
shown). In comparison to the control group, the PCOS
women (also according to the MTHFR genotypes) main-
tained the same differences in hormonal data observed in
Table 1 (data not shown). In particular, no differences in
serum vitamin B12 and folate levels were observed in PCOS and
control women according to the genotype groups (Table 3).
In Fig. 1, the serum Hcy levels are shown in PCOS and
control women according to the different groups of MTHFR
polymorphism.
In the control group, the mean serum Hcy levels were
significantly (P  0.05) higher in women with the TT geno-
type compared with CC and/or CT genotypes (22.0 7.8 vs.
9.7  2.9 and 11.0  3.2 mol/liter, respectively; Fig. 1). On
the contrary, no significant difference was detected between
the three groups of different polymorphisms in PCOS pa-
tients (10.4  3.1, 10.9  3.8, and 11.5  3.9 mol/liter, for
CC, CT, and TT genotypes, respectively; Fig. 1).
No significant difference was found in serum Hcy levels
between subjects with PCOS and controls for CC genotype
[10.4  3.1 (sd) vs. 9.7  2.9 mol/liter] and for CT het-
erozygosity (10.9  3.8 vs. 11.0  3.2 mol/liter; Fig. 1). A
significant (P  0.05) difference was observed between sub-
jects with PCOS and controls with TT homozygosity (11.5
3.9 vs. 22.0  7.8 mol/liter; Fig. 1).
After OGTT, four (5.7%) women with PCOS were di-
agnosed to have glucose intolerance, whereas only one
(1.4%) woman in the control group had glucose intoler-
ance. AUCinsulin and AUCglucose/AUCinsulin ratio were sig-
nificantly (P  0.05) higher in PCOS than in control
women, whereas no statistical difference was observed in
AUCglucose (Table 1).
No difference was observed between and within MTHFR
genotypes in fasting glucose levels and in AUCglucose after
OGTT (Table 4). The fasting insulin levels were significantly
(P  0.05) higher in PCOS women in comparison with con-
trols without a difference within and between MTHFR ge-
notypes (Table 4).
The AUCinsulin and AUCglucose/AUCinsulin ratio were also
significantly (P  0.05) higher in PCOS women than in con-
trol women in all MTHFR genotypes without difference be-
tween MTHFR genotypes (Table 4).
A significant (P  0.05) relation was detected between
Hcy levels and fasting insulin, AUCinsulin, and AUCglucose/
TABLE 2. Frequency of different genotypes in PCOS and control
women
Genotype
CC CT TT
PCOS (n  70) 16 (22.9) 41 (58.5) 13 (18.6)
Controls (n  70) 17 (24.3) 38 (54.3) 15 (21.4)
Data are expressed as number (%).
TABLE 1. Clinical and biochemical data of women with PCOS
and controls
PCOS
(n  70)
Controls
(n  70)
Age (yr) 22.5  4.3 21.9  3.2
BMI (kg/m2) 24.1  3.1 23.8  3.7
Waist/hip ratio 0.88  0.1 0.85  0.3
Ferriman-Gallwey score 12.1  1.1a 5.2  0.3
FSH (IU/liter) 9.5  1.2 9.8  1.3
LH (IU/liter) 30.6  3.7a 14.6  1.5
PRL (ng/ml) 10.8  0.7 11  0.8
E2 (pmol/liter) 167.9  18.1
a 149.8  17.3
P (nmol/liter) 1.1  0.5a 1.7  0.7
17-OHP (nmol/liter) 43.9  0.2a 42.7  0.3
T (nmol/liter) 2.8  0.3a 1.7  0.2
A (nmol/liter) 7.14  0.7a 4.44  0.9
DHEAS (mol/liter) 4416  401a 3618  343
SHBG (nmol/liter) 29.1  5.2a 50.3  8.4
IGF-I (nmol/liter) 47.6  2.1a 33.5  8.5
Vitamin B12 (ng/ml) 377.4  101.5 384.5  128.7
Folate (nmol/liter) 8.6  2.4 8.5  2.3
Hcy (mol/liter) 11.3  3.7 12.2  4.5
Fasting glucose (mmol/
liter)
6.9  3.1 5.6  2.9
Fasting insulin (U/ml) 21.1  6.7a 7.8  2.1
OGTT
AUCglucose 1254  562 1216  458
AUCinsulin 6063  1474
a 2587  397
AUCglucose/AUCinsulin
ratio
0.19  0.33a 0.49  0.40
Data are expressed as mean  SD.
a P  0.05 vs. control group.
TABLE 3. Serum vitamin B12 and folate levels in PCOS and
control women according to MTHFR genotype
Genotype
PCOS Control
Vitamin B12
(ng/ml)
Folate
(nmol/liter)
Vitamin B12
(ng/ml)
Folate
(nmol/liter)
CC 350.1  98.2 8.9  2.3 377.2  128.3 8.6  2.3
CT 396.3  102.3 8.4  2.2 369.7  114.2 8.3  2.1
TT 378.9  99.6 8.7  2.4 400.6  97.2 8.9  2.2
Data are expressed as mean  SD.
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AUCinsulin ratio in PCOS women (r  0.41, r  0.52, and
r  0.58 for fasting insulin, AUCinsulin, and AUCglucose/
AUCinsulin ratio, respectively) and healthy women (r 
0.42, r  0.49, and r  0.56, for fasting insulin, AUCinsulin,
and AUCglucose/AUCinsulin ratio, respectively). In PCOS
and control women, these significant relations were main-
tained in CC and CT, but not in TT genotypes (Table 5).
Discussion
Only within the past 5 yr has Hcy taken its place among
other major risk factors such as cholesterol, smoking, and
obesity; it is now widely accepted as a major independent
risk factor for cardiovascular, cerebrovascular, and periph-
eral vascular disease (21).
Several in vitro (37–45) and in vivo (46–50) studies have
shown that Hcy acts on the cardiovascular system with a
direct toxicity on the endothelium. In particular, Hcy in-
creases DNA synthesis in vascular smooth muscle cells in-
ducing its proliferation (48, 40–45), whereas it blocks the
regeneration of endothelial cells (47) and causes oxidation
of low lipoprotein (49–51). One of the most frequent causes
of increased plasma levels of Hcy is a decreased activity of
5,10-MTHFR (18, 23, 26). In the original reports by Kang et
al. (23, 52), it had been suggested that there is a variant of the
MTHFR enzyme characterized by a thermolability and a
specific enzyme activity of approximately 50% of the normal
activity. This variant varies significantly in populations from
different geographic areas (23, 53, 54) and has been observed
in about 17% of subjects with CVD (55) and 28% of patients
with hyperhomocysteinemia and premature vascular dis-
ease (56).
In our study, we observed a high prevalence of homozy-
gosity for the C677T mutation as detected by other studies in
the Italian population (57–59). Furthermore, it is still not clear
whether homozygosity for MTHFR C677T mutation is a real
risk factor for CVD. This contention has been supported by
some studies (23, 52, 55–57, 60–64), but rejected by others (24,
65–72).
Currently, it is unknown whether Hcy may play a role in
the increased cardiovascular risk demonstrated in PCOS
women. Moreover, no study has focalized the attention on
the relationship between MTHFR polymorphism and Hcy
levels in women with PCOS.
Our data show that the Hcy levels in PCOS women are in
the normal range and similar to those obtained in our control
group. These findings are in contrast to the current literature
(73, 74). In fact, in these last studies (73, 74), elevated serum
Hcy concentrations were found in PCOS women, suggesting
that an alteration in Hcy metabolism may play a role in the
increased cardiovascular risk associated with PCOS. Fur-
thermore, there are many methodological differences. First of
all, in our study the assessment of Hcy concentrations was
performed using a more sensitive and specific assay, that is
HPLC. In addition, our sample of women was larger and
younger in comparison to the subjects studied by other au-
thors (73, 74). Finally, our study population was based on a
sample of subjects in Hardy-Weinberg equilibrium for the
allelic distribution of MTHFR genotypes, whereas nonge-
netic evaluation was performed by Yarali et al. (73) and
Loverro et al. (74).
Our findings are similar to those obtained by Sills et al. (27).
In this last study (27), serum androgens and fasting insulin
levels, but not Hcy concentrations, were significantly higher
in women with polycystic ovaries. Furthermore, also in this
last study (27), no DNA analysis was performed.
Our study confirms that the homozygosity of C677T
MTHFR mutation is associated with high levels of Hcy in
healthy women (23, 75). Furthermore, a lack of significant
association between the MTHFR mutation and high levels of
Hcy in PCOS women was observed, not precluding the pos-
sibility that the C677T mutation could be a marker for vas-
cular disease in PCOS women because this was not the aim
of our study.
No association was found between genotype and fasting
Hcy in subjects with plasma folate levels at or above the
median (15 nmol/liter; Ref. 76). Plasma Hcy concentrations
are not different between genotypes when folate concentra-
tions are above the median, whereas elevated Hcy concen-
trations have been observed in subjects with TT genotype
when folate levels are below the median or the lowest quar-
tile (68).
Many studies have shown that plasma Hcy concentration
is inversely related to blood levels of vitamin B12 and folate
(77). The highest Hcy concentrations observed in TT women
are due to a low dietary intake of vitamins and to a major
susceptibility to this inadequate alimentary support (31, 78).
On the contrary, when folate consumption is high, the TT
genotype has little effect on Hcy levels (18).
On the basis of these considerations, to obtain a homoge-
neous group of subjects and to eliminate the confounding
factors due to dietary factors, we enrolled only PCOS and
healthy women with a low intake of folate (24). Because of
the limitations and complexity of various approaches to eval-
uate food intake and the nutrients (79), we did not use any
semiquantitative questionnaire or diet-quality scores, but
only a measurement of serum folate. The cut-off established
in the present study was very close, and it was lower in
comparison to the one used by Somekawa et al. (13.6 nmol/
liter; Ref. 80). Thus, the differences in Hcy value were due
probably only to genetic (i.e. C677T MTHFR mutation) or
metabolic (i.e. PCOS) factors.
FIG. 1. Serum Hcy levels according to the genotype distribution in
PCOS and controls. Values are expressed as mean  SD. *, P  0.05
vs. all genotypes in PCOS women and vs. CC and CT genotypes in
control women.
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The exact significance of the absence of an association
between MTHFR C677T mutation and serum Hcy levels in
women with PCOS is unknown. It is possible to hypothesize
that in PCOS women, the hormonal pattern (i.e. relative
hyperestrogenism) may amplify the responsiveness of ther-
molabile MTHFR to plasma folate levels, inducing an ab-
sence of relationship between TT genotype and high Hcy
levels in subjects with low folate intake. To explain the re-
lationship between MTHFR C677T mutation and Hcy level
in PCOS women, our research group is performing an eval-
uation of the effect of folate repletion or of a methionine load
on Hcy concentrations in this subset of women. In fact, the
use of methionine challenge reveals an additional 27% of
patients with hyperhomocysteinemia and would have led to
classification of more than 40% fewer subjects as being hy-
perhomocysteinemic (77, 81). Indeed, fasting and post-load
elevations in Hcy had independent effects on the cardiovas-
cular risk and had a multiplicative effect when present to-
gether. The relative risk for a subject with an elevated fasting
Hcy was only 1.6 [95% confidence interval (CI), 1.0–2.2] and
that for an elevated post-load was only 1.5 (95% CI, 1.0–2.2),
whereas for subjects with both elevated fasting and post-load
levels, the relative risk was 2.5 (95% CI, 1.7–3.5; Ref. 77).
Plasma levels of insulin seem to influence Hcy metabolism
through effects on glomerular filtration or by influencing
activity of pivotal enzymes in Hcy metabolism, as MTHFR
and cystathione--synthase (CBS). In animal model, Fonseca
et al. (82, 83) have shown that fasting plasma insulin corre-
lated significantly and positively with plasma Hcy and
MTHFR activity and negatively with CBS activity, support-
ing the hypothesis that insulin may regulate Hcy metabolism
through regulation of the two hepatic key enzymes. The
activity of the CBS and MTHFR was also affected when
insulin and glucose were added to hepatocytes in vitro (84).
More recently, it has been demonstrated that insulin has a
direct role in the expression of CBS in the liver (85).
In normal weight, overweight, and obese premenopausal
women, the Hcy levels are independently associated with
insulin resistance (86), and this association seems to be stron-
ger in hyperinsulinemic obese subjects (87). In a large ob-
servational study, Meigs et al. (88) confirmed that the fasting
plasma Hcy levels are directly associated with insulin
resistance.
Furthermore, the data regarding the relationship between
insulin, insulin resistance, and Hcy levels are still contrasting
(89–92). Metformin administration in women with PCOS can
lead to the increase in Hcy levels (93). Gursu et al. (94) have
shown that Hcy concentrations are decreased in experimen-
tally induced insulin-dependent diabetes mellitus, and in-
sulin administration normalizes Hcy levels in a dose-depen-
dent manner.
In the present study, to evaluate the insulin resistance as
a possible mechanism to explain the different Hcy concen-
trations in TT subjects with and without PCOS, AUCglucose,
AUCinsulin, and AUCglucose/AUCinsulin ratio were measured
in each genotype group. Our data on the total study popu-
lation with and without PCOS confirm that Hcy levels are
directly related to insulin level after OGTT.
AUCglucose, AUCinsulin, and AUCglucose/AUCinsulin ratio
were significantly higher in the PCOS group than in the
control group without differences within and between
MTHFR genotypes. Moreover, the linear relation analysis
between Hcy levels and AUCglucose, AUCinsulin, and
AUCglucose/AUCinsulin ratio showed a statistical signifi-
cance only in CC and CT genotypes. In fact, in PCOS and
control women, this significance was lost considering the TT
genotype. In this view, our data suggest that the higher
insulin resistance observed in PCOS women did not influ-
ence negatively the MTHFR activity. In addition, the relation
between insulin resistance and Hcy levels in the different
MTHFR genotypes could explain the difference in the results
obtained in the different studies on this issue (86–94). Un-
fortunately, this remains unclear because in our study, sub-
jects with TT genotype have Hcy levels unrelated to insulin
resistance.
In conclusion, in the present study, we have demonstrated
that the mean serum Hcy levels are not increased in women
with PCOS and that the thermolabile MTHFR enzyme in-
fluences the serum Hcy concentrations only in healthy
women, whereas it is not related to Hcy levels in PCOS. The
TABLE 4. Glucose and insulin levels at baseline and after OGTT in PCOS and control women according to MTHFR genotypes
PCOS Controls
CC CT TT CC CT TT
Fasting
Glucose (mmol/liter) 6.9  3.2 6.9  3.0 6.8  2.9 5.6  3.1 5.6  3.0 5.5  2.8
Insulin (U/ml) 21.5  6.9a 21.3  6.7a 20.4  6.8a 7.8  2.1 7.9  2.2 7.7  2.0
OGTT
AUCglucose 1266  516 1242  569 1281  572 1239  479 1218  466 1187  450
AUCinsulin 7785  1476
a 7696  1443a 7419  1452a 2566  388 2608  414 2557  371
AUCglucose/AUCinsulin ratio 0.20  0.35
a 0.18  0.33a 0.19  0.33a 0.52  0.41 0.48  0.39 0.47  0.38
Data are expressed as mean  SD.
a P  0.05 vs. control group.
TABLE 5. Linear relation between Hcy levels and fasting glucose
and insulin levels, AUCglucose, AUCinsulin, and AUCglucose/AUCinsulin
ratio after OGTT in PCOS and control women according to
MTHFR genotypes
PCOS (r) Controls (r)
CC CT TT CC CT TT
Fasting
Glucose (mmol/liter) 0.28 0.25 0.26 0.24 0.20 0.23
Insulin (U/ml) 0.42a 0.45a 0.10 0.41a 0.44a 0.18
OGTT
AUCglucose 0.32 0.27 0.27 0.28 0.25 0.26
AUCinsulin 0.61
a 0.58a 0.19 0.46a 0.53a 0.23
AUCglucose/AUCinsulin ratio 0.64
a 0.61a 0.21 0.60a 0.62a 0.25
a P  0.05.
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insulin resistance seems to play a role in Hcy metabolism
only in women without thermolabile MTHFR enzyme.
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